FY2027 EPS Estimate for Compass Therapeutics Cut by Analyst

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - HC Wainwright cut their FY2027 EPS estimates for shares of Compass Therapeutics in a report released on Monday, April 28th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.44) for the year, down from their previous forecast of ($0.02). HC Wainwright has a "Buy" rating and a $24.00 price target on the stock. The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Compass Therapeutics' FY2028 earnings at ($0.13) EPS.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01).

Other equities research analysts have also issued reports about the stock. Piper Sandler began coverage on shares of Compass Therapeutics in a report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 target price on the stock. D. Boral Capital reiterated a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a report on Monday, April 28th. Jefferies Financial Group boosted their price target on Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a report on Monday, February 10th. Leerink Partners raised Compass Therapeutics from a "market perform" rating to an "outperform" rating and lifted their target price for the company from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Finally, Guggenheim reaffirmed a "buy" rating on shares of Compass Therapeutics in a research note on Tuesday, April 22nd. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $13.38.

Compass Therapeutics Stock Down 6.7 %

NASDAQ CMPX traded down $0.13 on Thursday, reaching $1.74. The company had a trading volume of 458,809 shares, compared to its average volume of 883,495. The stock has a market cap of $239.92 million, a price-to-earnings ratio of -4.69 and a beta of 1.40. The stock's 50 day moving average is $2.08 and its 200-day moving average is $2.10. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $4.08.

Insider Buying and Selling at Compass Therapeutics

In other news, insider Jonathan Anderman bought 20,000 shares of the company's stock in a transaction on Monday, April 7th. The shares were purchased at an average price of $1.54 per share, with a total value of $30,800.00. Following the transaction, the insider now directly owns 21,000 shares in the company, valued at $32,340. This represents a 2,000.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Carl L. Gordon sold 3,571,428 shares of Compass Therapeutics stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. Corporate insiders own 28.50% of the company's stock.

Institutional Trading of Compass Therapeutics

A number of large investors have recently bought and sold shares of CMPX. Barclays PLC grew its position in shares of Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company's stock valued at $314,000 after purchasing an additional 112,614 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Compass Therapeutics by 921.6% in the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock worth $573,000 after buying an additional 356,352 shares during the last quarter. Geode Capital Management LLC grew its position in Compass Therapeutics by 0.8% in the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company's stock worth $4,251,000 after acquiring an additional 19,095 shares in the last quarter. Bleakley Financial Group LLC raised its position in Compass Therapeutics by 250.7% during the fourth quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company's stock valued at $58,000 after purchasing an additional 28,589 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Compass Therapeutics by 25.2% in the 4th quarter. Renaissance Technologies LLC now owns 278,600 shares of the company's stock worth $404,000 after purchasing an additional 56,000 shares in the last quarter. 68.43% of the stock is owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.